India: Generics And Innovators - Saying I Do And Doing Battle

Arguably, the opening of the Indian economy and India's Patents (Amendment) Act 2005 has had a most significant impact in the area of pharmaceuticals. With the new regime, the $8 billion Indian pharmaceutical industry has been forced to adapt and recast its business models. The introduction of product patents has provided a fresh impetus to domestic research programs whilst firms continue to leverage on existing product portfolios which are centred on generics. It is a time of foreign investment, simultaneously Indian companies are aggressively pursuing global opportunities. With an unprecedented number of mergers, acquisitions, alliances and increased litigation in recent years, making sense of developments is no easy task. In the first of our updates, we look at some recent developments that indicate that generics and innovators are increasingly co-existing even whilst older combative positions persist.

Arranged Marriage

Moving to generic drugs rather than the branded drugs that currently predominate and are favoured by patients in Japan is a key factor in the Japanese government's proposed measures to slash medical costs. Little surprise then that Daiichi Sankyo came courting for a majority stake in one of India's premier drug companies, Ranbaxy, in June this year. The transaction, the largest potential deal in the Indian pharmaceutical industry, is expected to be worth up to $4.7 billion and will leave Ranbaxy a subsidiary of Daiichi by mid 2009. The deal is expected to give Ranbaxy access to Daiichi's R&D while the Japanese company is expected to benefit from low manufacturing costs in the Indian sub-continent. Further, the Daiichi brand name is expected to develop a market for generics in Japan as well as give the group access to generic drug markets in 50 different countries through Ranbaxy. Whether it will be a marriage made in heaven remains to be seen. Like with any arranged alliance, the parties may well be discovering certain home truths. Recent reports suggest that the US government may initiate legal action against Ranbaxy for allegedly forging documents and selling sub-standard products. Both companies have however sought to quell speculation that the deal is under question. Ranbaxy has denied any wrong doing and for the moment Daiichi is the loyal partner aware of Ranbaxy's past. Whichever way the deal goes, the very size of the deal is likely to trigger more than a few attempts at cross-cultural coupling.


That the pharmaceutical industry has been experimenting with various options can be seen from the fact that at least a few companies in India have been going the other way. "De-merging" the generics business to form a separate division concentrating on new research would appear to be one way of addressing India's traditional Achilles Heel, new research. Nicholas Piramal de-merged its R&D unit into an independent company, NPIL, last year and it is reported to have 13 compounds in its pipeline with at least four in clinical trials. Glenmark Pharmaceuticals also announced it would spin off its generics business to a new company Glenmark Generics, which will handle generic formulations and APIs with Glenmark Pharmaceuticals continuing to directly manage novel R&D. Dr. Reddy's Laboratories and Sun Pharmaceuticals also announced spin-off companies along the same lines last year. Ranbaxy had attempted the same route, however given its recent venture, the fate of its spin-offs remains to be seen. Given the financial implications, the rest of Indian Pharma may well rethink their strategy if the Ranbaxy-Daiichi deal is finalised.


Such sweet harmony has not always prevailed. Whilst the Daiichi-Ranbaxy deal will challenge the present dominance of Indian-owned entities, at least a few companies appear to be fighting a battle to continue their generics business by challenging existing patents. The legislation, as it stands, provides for both pre-grant and post-grant oppositions. With "product

patents" allowable under the new regime, there has been a brisk business in pre and post-grant oppositions starting with the very first product patent to Roche (for its hepatitis C drug "Pegasys") being opposed by Wockhardt. In particular, patents covering anti-retroviral and anti-cancer drugs are being challenged by generic manufacturers. Roche's cancer drug "Tarceva" (Erlotinib), has been the subject of ongoing litigation with the Delhi High Court delivering a landmark judgement by refusing to keep Cipla's generic versions off the market in the public interest.

Additionally, health remains a sensitive political issue in India and patient groups and foreign NGOs have been active in pursuing oppositions. In spite of Gilead's voluntary licensing arrangements with a number of Indian generic manufacturers in relation to Gilead's AIDS Drug "Viread", a Brazilian health group has launched a pre-grant opposition against their patent. Roche's patent on "Valcyte" (valganciclovir), which survived pre-grant opposition, has been opposed by the Delhi Network of Positive People (DNP+) and a generic version is now expected to be marketed by Cipla. At least one decision resulted in rejection of the patent with Boehringer Ingelheim's patent application on the paediatric form of Nevirapine being successfully opposed pre-grant by AIDS patients groups in India. The decision suggests that the Indian Patent Office will adopt a rather strict patentability criteria for patents claiming HIV and cancer drugs.

In conclusion, with a GDP growth rate of 9.0% for the fiscal year 2007-2008, India remains the second fastest growing emerging economy in the world and pharmaceuticals remain one of the strong sectors of growth. The industry has unprecedented opportunities for both foreign and local companies and yet must operate in an environment where access to medicines at a reasonable price may well determine political fortunes. All this makes for a volatile climate with opportunities and risks for pharmaceutical businesses. In subsequent updates, we will endeavour to keep you informed of developments in the industry, both from a research and legal perspective.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Jacinta Flattery-O'Brien
In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions